Annovis

Annovis Bio Announces Positive Phase Two Efficacy Data for Treatment of Parkinson's Disease Data Shows Statistically Significant Improvements in Speed and Motor Function in PD Patients Annovis Bio to Request Meeting with FDA on Next Steps in Clinical Development Investor Conference Call to be Hosted Tuesday, October 5th, 2021, at…

Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer's Study Safety and tolerability data for Cohort 2 of the Discover Study reviewed by Data Safety Monitoring Board, allowing the study to proceed with the final cohort See more here

Annovis Bio CEO Wins 2021 PACT Enterprise Award for Life Sciences and Healthcare CEO See more here

Annovis Bio, Inc. Announces Closing of $50 Million Public Offering See more here

Annovis Bio, Inc. Announces Pricing of Public Offering See more here

Annovis Bio Appoints Accomplished Neuroscientist Dr. Cheng Fang as VP of Research See more here

Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer's Disease in Persons with Down Syndrome See more here

Annovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients See more here

Annovis Bio Signs GMP Manufacturing Agreement to Support Planned Late-Stage Studies See more here

Annovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury See more here